# Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma

> **NCT01064921** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- Stage III Squamous Cell Carcinoma of the Oropharynx
- Stage IV Squamous Cell Carcinoma of the Oropharynx

## Interventions

- **DRUG:** vorinostat
- **DRUG:** cisplatin
- **RADIATION:** radiation therapy
- **PROCEDURE:** Correlative Studies

## Key facts

- **NCT ID:** NCT01064921
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-19
- **Primary completion:** 2017-11-08
- **Final completion:** 2017-11-08
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2019-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064921, "Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01064921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*